Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders

  • End date
    Dec 1, 2024
  • participants needed
  • sponsor
    First Affiliated Hospital of Fujian Medical University
Updated on 1 December 2021
parkinson's disease


Alzheimer's disease, Parkinson's disease, and Huntington's disease are common neurodegenerative diseases. Tau is a microtubule-associated protein, and aggregated tau resulting from hyperphosphorylation is a pathological feature of a group of neurodegenerative diseases known as tauopathies. The 18F-T807 (AV1451) molecular probe is a novel molecularly targeted imaging agent that exhibits high affinity and good selectivity for tau.


In this study, 18F-T807 (AV1451) molecular probe PET/CT was used to monitor the regional distribution and the degree of deposition in patients with neurodegenerative diseases, and compared with clinical symptoms to evaluate its value in the early differential diagnosis of neurodegenerative diseases.

Condition neurodegenerative disorder, nervous system disorder, neurodegenerative disease, neurodegenerative disorders, Neurologic Disorders, Neurodegenerative Diseases
Treatment 18F-T807
Clinical Study IdentifierNCT04926259
SponsorFirst Affiliated Hospital of Fujian Medical University
Last Modified on1 December 2021


Yes No Not Sure

Inclusion Criteria

Patients or their families complain of significant memory impairment
Objective memory impairment (e.g., tests of article identification, recall, delayed memory)
Be able to obtain complete diagnosis and treatment records and be able to carry out long-term follow-up
Signed written consent

Exclusion Criteria

Psychiatric disorders: including anxiety disorder, affective disorder, severe psychosis, or drug-induced psychosis
Pregnancy or lactation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note